These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28953602)

  • 21. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
    Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
    Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
    J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
    J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-β pathway.
    Maetzler W; Stapf AK; Schulte C; Hauser AK; Lerche S; Wurster I; Schleicher E; Melms A; Berg D
    J Alzheimers Dis; 2011; 27(1):119-26. PubMed ID: 21765209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
    Nutu M; Zetterberg H; Londos E; Minthon L; Nägga K; Blennow K; Hansson O; Ohrfelt A
    Dement Geriatr Cogn Disord; 2013; 36(1-2):99-110. PubMed ID: 23860354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia.
    Borroni B; Premi E; Formenti A; Turrone R; Alberici A; Cottini E; Rizzetti C; Gasparotti R; Padovani A
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1049-55. PubMed ID: 26109553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.
    Wang ZY; Han ZM; Liu QF; Tang W; Ye K; Yao YY
    Int Psychogeriatr; 2015 Sep; 27(9):1429-38. PubMed ID: 25851548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cerebrospinal fluid and plasma biomarkers for dementia with lewy bodies].
    Kasuga K; Ikeuchi T
    Brain Nerve; 2012 May; 64(5):505-13. PubMed ID: 22570064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-abundant cerebrospinal fluid proteome alterations in dementia with Lewy bodies.
    Dieks JK; Gawinecka J; Asif AR; Varges D; Gmitterova K; Streich JH; Dihazi H; Heinemann U; Zerr I
    J Alzheimers Dis; 2013; 34(2):387-97. PubMed ID: 23254635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.
    Spies PE; Melis RJ; Sjögren MJ; Rikkert MG; Verbeek MM
    J Alzheimers Dis; 2009; 16(2):363-9. PubMed ID: 19221426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies.
    Aarsland D
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S144-8. PubMed ID: 26411499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
    Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
    Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.
    Lemstra AW; de Beer MH; Teunissen CE; Schreuder C; Scheltens P; van der Flier WM; Sikkes SA
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):113-118. PubMed ID: 27794030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.